SLC2A1 Variants and Diabetic Nephropathy

Completed

• Conditions: Diabetic Nephropathy.

• Registration Number: NCT01768611
• Lead Sponsor: University of Sao Paulo General Hospital

Brief Summary

Cells damaged by hyperglycemia are unable to downregulate glucose entrance in presence of high extracellular glucose resulting in intracellular activation of deleterious biochemical pathways. Expression of GLUT-1, the major glucose transporter in mesangial cells, is increased and participates in the induction of diabetic nephropathy. Variants in the gene encoding GLUT-1 (SLC2A1) have been associated to this diabetic complication. The aim of this study was to test whether polymorphisms in SLC2A1 confer susceptibility to diabetic nephropathy in Brazilian type 1 diabetes patients.

Detailed Description

In this study, 449 patients, included between October 2004 and October 2012, were sorted into three groups according to diabetic nephropathy stages: without (persistent normoalbuminuria, n=248), incipient (microalbuminuria, n=82) and overt diabetic nephropathy (macroalbuminuria or proteinuria or renal replacement therapy, n=119). Measurements of urinary albumin-to-creatinine ratio (ACR) or urinary albumin excretion rate (UAER) were used to define DN: patients with persistent normoalbuminuria (\<30 mg/g creatinine or \<20 μg/min) were classified as without DN (n=248); patients presenting persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min) were classified as having incipient DN (n=82); and patients presenting persistent macroalbuminuria (\>300 mg/g creatinine or \>200 µg/min), proteinuria (\>500 mg/24 h) or renal replacement therapy were classified as having overt DN (n=119). Genotyping of polymorphisms was performed by Real Time PCR using fluorescent -labelled probes.

Study Timeline

• Study Start: 2004-10
• Primary Completion: 2012-10
• Study Completion: 2012-10
• Study First Submitted: 2012-12-17
• Status Verified: 2013-01
• Study First Submitted QC: 2013-01-11
• Study First Posted: 2013-01-15
• Last Update Submitted: 2013-01-15
• Last Update Posted: 2013-01-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 449

Inclusion Criteria

• Overt 10 years of Diabetes Mellitus

Exclusion Criteria

• Patients presenting autoimmune diseases, HIV or HCV infections
• Patients with glomerular filtration rate < 60 mL min-1 1.73 m2 without diabetic retinopathy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasmatic Creatinine	Two years

Trial Locations

Locations (1)

Faculdade de Medicina da USP; 🇧🇷 São Paulo, SP, Brazil